Heptares’ Patents Covering Stabilised Receptor (StaR®) Technology Granted in Europe and Japan

Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery

Heptares Scientists Report The First Use of Structure-Based Design to Discover GPCR-Targeted Drug Candidate

Heptares Expands Executive Management Team with Appointment of Daniel Grau as President

Company to advance pipeline in neurological and metabolic areas, while harnessing broader discovery platform through alliances

Heptares Scientists Generate New Insight Into Caffeine's Molecular Pharmacology To Drive Design Of Next-Generation CNS Therapeutics

First 3-D X-ray Co-structures of Caffeine and other Xanthines Bound to G-Protein Coupled Receptor (GPCR) Published in the Journal Structure

Heptares Biophysical Mapping™ Featured in the Journal of Medicinal Chemistry

New Technology Elucidates GPCRs and Accelerates Structure-Based Design of GPCR Targeted Medicines

AstraZeneca and Heptares Collaborate to Investigate Important GPCR Drug Targets

AstraZeneca and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs).

Research Reveals First-Ever Structure of GPCR Drug Target Bound to Natural Ligand

Heptares Grants Shire an Exclusive Option to License Novel Adenosine A2A Antagonist

Novel Small Molecule Candidate Best-in-Class Potential in Treatment of CNS Diseases

Heptares and Takeda Initiate Drug Discovery Collaboration Focused on GPCR linked to CNS Disorders

Deal Includes £4.5 Million Upfront Cash and Equity, up to £60.5 Million in Future Milestone Payments, and Royalties on Product Sales

Heptares Therapeutics’ Scientists Deploy StaRs^® to Unlock the Power of Fragment Screening for Intractable GPCR Drug Targets

Results Published in Latest Edition of Methods in Enzymology